AIMS: To demonstrate the bioequivalence of macitentan/tadalafil fixed-dose combination (FDC) tablets with single-component tablets of macitentan and tadalafil in healthy subjects. METHODS: Studies AC-077-101 and AC-077-103 were single-centre, open-label, single-dose, 2-period, randomized, crossover Phase 1 studies conducted in healthy subjects. Two FDCs were investigated: FDC-1 and FDC-2 in Study AC-077-101 and FDC-2 in Study AC-077-103. Both FDCs contained 10 mg/40 mg of macitentan/tadalafil and differed in excipients and coating materials used. In both studies, pharmacokinetic sampling over 216 hours was conducted, and pharmacokinetic parameters were derived using noncompartmental methods. RESULTS: Bioequivalence of macitentan, its active metabolite ACT-132577, and tadalafil was established for FDC-2 in both studies AC-077-101 and AC-077-103 in which tadalafil as a single component was sourced from the USA and EU, respectively, to fulfil regional regulatory requirements. The area under the plasma concentration-time curve and maximum plasma concentration with 90% confidence intervals of all components were entirely within the bioequivalence limits (0.8000-1.2500). No subject died and no serious adverse events were reported in either studies. CONCLUSION: The FDC-2 tablet containing 10 mg/40 mg of macitentan/tadalafil was bioequivalent to the free combination of 10 mg macitentan and 40 mg tadalafil (both US and EU sourced). Macitentan and tadalafil were well tolerated when administered as FDC or as a free combination.

Actelion Pharmaceuticals Ltd Allschwil Switzerland

Aixial s r o Brno Czech Republic

Clinical Research Services Mannheim GmbH Mannheim Germany

Idorsia Pharmaceuticals Ltd Allschwil Switzerland

Reven LLC Golden CO USA

See more in PubMed

D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343‐349. PubMed

Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J am Coll Cardiol. 2013;62(25 Suppl):D60‐D72. PubMed

Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809‐818. PubMed

Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med. 2009;361(19):1864‐1871. PubMed

Falk JA, Philip KJ, Schwarz ER. The emergence of oral tadalafil as a once‐daily treatment for pulmonary arterial hypertension. Vasc Health Risk Mana. 2010;6:273‐280. PubMed PMC

Federal Food , Drug and Cosmetic Act (FD&C Act). Chapter V, Part A, Sec. 355 (b; 2). 1938.

European Medicines Agency , Evaluation of Medicines for Human Use, CPMP. Guideline on the investigation of bioequivalence. CPMP/QWP/EWP/1401/98 Rev. 1. London: 2010.

Zimmermann T. Validation of an analytical method for the determination of ACT‐064992 and its metabolite ACT‐132577 in human plasma samples by LC MS/MS, Actelion study no. BA 13.225. 2014.

Steurer A. Supplementary validation of an analytical method for the determination of ACT‐064992 and its metabolite ACT‐132577 in human plasma samples by LC MS/MS, Actelion study no. BA 14.033. 2016.

Steigerwald K. Validation of determination of tadalafil in plasma samples of subjects. ACC (Analytical Clinical Concept) 316B14‐Val. 2014.

Forgue ST, Patterson BE, Bedding AW, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006;61(3):280‐288. PubMed PMC

Sidharta PN, van Giersbergen PL, Halabi A, Dingemanse J. Macitentan: entry‐into humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol. 2011;67(10):977‐984. PubMed PMC

Sidharta PN, Treiber A, Dingemanse J. Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan. Clin Pharmacokinet. 2015;54(5):457‐471. PubMed PMC